Where to buy 4′-Methyl-α-pyrrolidinopropiophenone (MPPP) for sale online


4′-Methyl-α-pyrrolidinopropiophenone (often called 4-MePPP, MPPP, or MαPPP) is categorized as a stimulant drug and falls under the substituted cathinone class. Its structural resemblance to α-PPP is striking, with the only distinction being adding a single methyl group at the para position on the phenyl ring.
During the late 1990s and early 2000s, 4-MePPP was available for sale in Germany as a designer drug, along with several other derivatives within the pyrrolidinophenone family. Despite not gaining the same international recognition as its more well-known counterparts, such as α-PPP and MDPV, 4-MePPP has occasionally been identified as an ingredient in grey-market “bath salt” mixtures like “NRG-3.”

IUPAC name
CAS Number28117-80-8
1313393-58-6 (hydrochloride)
PubChem CID6430745
CompTox Dashboard (EPA)DTXSID80891438
Chemical and physical data
Molar mass217.312 g·mol−1


In the United States, 4-MePPP is classified as a Schedule I controlled substance due to its status as a positional isomer of alpha-pyrrolidinopentiophenone (α-PVP).


1. What is 4-MePPP?

  • 4-MePPP, short for 4′-Methyl-α-pyrrolidinopropiophenone, is a synthetic compound that belongs to the family of substituted cathinones. It is chemically related to α-pyrrolidinopentiophenone (α-PVP) and is known for its stimulant effects.

2. What are its effects?

  • 4-MePPP produces stimulant effects, including increased alertness, energy, and euphoria. It may also increase heart rate, enhance mood, and heighten sociability.

3. Is 4-MePPP legal?

  • In many countries, including the United States, 4-MePPP is considered a controlled substance and is illegal to manufacture, possess, or distribute without proper authorization. Laws regarding its legality can vary from place to place, so it’s essential to check local regulations.

4. Is 4-MePPP safe to use?

  • The safety of 4-MePPP has not been well-studied, and its use carries risks. Users should be aware of potential adverse effects, including cardiovascular problems, anxiety, paranoia, and addiction. Due to its unregulated nature, the purity and quality of 4-MePPP purchased on the black market can vary, increasing potential harm.

5. Can it be detected in drug tests?

  • Yes, 4-MePPP can be detected in drug tests, particularly in urine tests. It’s important to note that substances like 4-MePPP are often not included in standard drug screenings, but specialized tests can detect its presence.

6. What are the street names for 4-MePPP?

  • Street names for 4-MePPP can vary by region and may include nicknames like “MEP,” “MPPP,” or other variations.

7. Is 4-MePPP associated with any health risks?

  • Yes, using 4-MePPP can be associated with various health risks, including cardiovascular problems, anxiety, paranoia, and potential addiction. Limited research on its long-term effects makes it difficult to assess the full extent of its risks.

8. Can 4-MePPP be used for medical purposes?

  • No, 4-MePPP is not approved for any medical use and is primarily encountered as a recreational or illicit substance.

9. What should I do if I suspect someone is using 4-MePPP?

  • If you suspect someone is using 4-MePPP or any other illicit substance, it’s essential to encourage them to seek professional help. Substance abuse can have severe health and social consequences, and early intervention is crucial.


  1. “Cannabinoider har föreslagits bli kategoriserade som en hälsorisk.” [Cannabinoids have been proposed for classification as a health risk].
    • Source: Folkhälsomyndigheten [The Public Health Authority] (in Swedish). Retrieved 29 June 2015.
  2. “Undersökningar om metabolismen och toxikologisk detektion av den nya designerdrogen 4′-metyl-alfa-pyrrolidinopropiophenone i urin med hjälp av gaschromatografi-masspektrometri.” [Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry].
    • Authors: Springer D, Peters FT, Fritschi G, Maurer HH
    • Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
    • Year: June 2002
    • DOI: 10.1016/S1570-0232(01)00578-5
    • PMID: 12015267
  3. “Identifiering av cytochrome p450-enzymer som är involverade i metabolismen av 4′-metyl-alfa-pyrrolidinopropiophenone, en ny schemalagd designerdrog, i mänskliga levermikrosomer.” [Identification of cytochrome p450 enzymes involved in the metabolism of 4′-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes].
    • Authors: Springer D, Paul LD, Staack RF, Kraemer T, Maurer HH
    • Journal: Drug Metabolism and Disposition
    • Year: August 2003
    • DOI: 10.1124/dmd.31.8.979
    • PMID: 12867484
  4. “Metabolismen av den nya designerdrogen alpha-pyrrolidinopropiophenone (PPP) och den toxikologiska detektionen av PPP och 4′-metyl-alfa-pyrrolidinopropiophenone (MPPP) studerades i råtts urin med hjälp av gaschromatografi-masspektrometri.” [Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry].
    • Authors: Springer D, Fritschi G, Maurer HH
    • Journal: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
    • Year: November 2003
    • DOI: 10.1016/j.jchromb.2003.07.008
    • PMID: 14581066
  5. “Kemi, farmakologi, toxikologi och levermetabolism av designerdroger av amfetamin (ecstasy), piperazin och pyrrolidinofenontyper: en sammanfattning.” [Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis].
    • Authors: Maurer HH, Kraemer T, Springer D, Staack RF
    • Journal: Therapeutic Drug Monitoring
    • Year: April 2004
    • DOI: 10.1097/00007691-200404000-00007
    • PMID: 15228152
  6. “Metabolism av designerdroger som missbrukas.” [Metabolism of designer drugs of abuse].
    • Authors: Staack RF, Maurer HH
    • Journal: Current Drug Metabolism
    • Year: June 2005
    • DOI: 10.2174/1389200054021825
    • PMID: 15975043
  7. “Analys av NRG ‘legal highs’ i Storbritannien: identifiering och bildning av nya katinoner.” [Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones].
    • Authors: Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J
    • Journal: Drug Testing and Analysis
    • Year: September 2011
    • DOI: 10.1002/dta.204
    • PMID: 21960541
  8. “Listor över: Schemalagda åtgärder för kontrollerade ämnen Reglerade kemikalier.” [Lists of: Scheduling Actions Controlled Substances Regulated Chemicals (PDF)].
    • Source: U.S. Department of Justice
    • Year: February 2023
    • Retrieved: 5 March 2023

Leave a Comment

Your email address will not be published. Required fields are marked *